Synthetic Biologics, Inc. (SYN) Short Interest Update
Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 5,632,047 shares, a decline of 10.2% from the November 15th total of 6,268,579 shares. Based on an average daily volume of 710,788 shares, the days-to-cover ratio is presently 7.9 days. Currently, 4.9% of the company’s shares are sold short.
Synthetic Biologics (NYSEAMERICAN:SYN) opened at $0.52 on Friday. Synthetic Biologics has a 12-month low of $0.41 and a 12-month high of $1.05.
Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10).
A number of research analysts have weighed in on the stock. BidaskClub cut shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, November 4th. Zacks Investment Research cut shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, ValuEngine cut shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $3.92.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.